NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$1.1b

Last Updated

2021/05/17 00:48 UTC

Data Sources

Company Financials +

Executive Summary

CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. More Details


Snowflake Analysis

Reasonable growth potential and overvalued.


Similar Companies

Share Price & News

How has CryoLife's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CRY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: CRY's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-5.4%

CRY

-2.5%

US Medical Equipment

-1.7%

US Market


1 Year Return

30.9%

CRY

34.4%

US Medical Equipment

50.8%

US Market

Return vs Industry: CRY underperformed the US Medical Equipment industry which returned 34.4% over the past year.

Return vs Market: CRY underperformed the US Market which returned 50.8% over the past year.


Shareholder returns

CRYIndustryMarket
7 Day-5.4%-2.5%-1.7%
30 Day27.2%-3.2%-1.5%
90 Day16.3%-3.1%0.4%
1 Year30.9%30.9%35.4%34.4%53.3%50.8%
3 Year8.4%8.4%68.0%64.1%61.5%51.4%
5 Year153.2%153.2%151.3%133.0%125.8%100.7%

Long-Term Price Volatility Vs. Market

How volatile is CryoLife's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CryoLife undervalued compared to its fair value and its price relative to the market?

3.81x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CRY's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CRY's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CRY is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: CRY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CRY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CRY is good value based on its PB Ratio (3.8x) compared to the US Medical Equipment industry average (4.4x).


Future Growth

How is CryoLife forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

80.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: CRY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CRY's is expected to become profitable in the next 3 years.

Revenue vs Market: CRY's revenue (12.5% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: CRY's revenue (12.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CRY's Return on Equity is forecast to be high in 3 years time


Past Performance

How has CryoLife performed over the past 5 years?

-66.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CRY is currently unprofitable.

Growing Profit Margin: CRY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CRY is unprofitable, and losses have increased over the past 5 years at a rate of 66.6% per year.

Accelerating Growth: Unable to compare CRY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CRY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.5%).


Return on Equity

High ROE: CRY has a negative Return on Equity (-4.42%), as it is currently unprofitable.


Financial Health

How is CryoLife's financial position?


Financial Position Analysis

Short Term Liabilities: CRY's short term assets ($235.7M) exceed its short term liabilities ($58.0M).

Long Term Liabilities: CRY's short term assets ($235.7M) do not cover its long term liabilities ($439.5M).


Debt to Equity History and Analysis

Debt Level: CRY's debt to equity ratio (104.7%) is considered high.

Reducing Debt: CRY's debt to equity ratio has increased from 37.4% to 104.7% over the past 5 years.

Debt Coverage: CRY's debt is not well covered by operating cash flow (2.2%).

Interest Coverage: CRY is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Dividend

What is CryoLife current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CRY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CRY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CRY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: CRY is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CRY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.2yrs

Average management tenure


CEO

Pat Mackin (53 yo)

6.67yrs

Tenure

US$3,415,458

Compensation

Mr. James Patrick Mackin, also known as Pat, has been the Chief Executive Officer and President of CryoLife Inc. since September 02, 2014 and has been its Chairman since May 2015. Mr. Mackin served as Pres...


CEO Compensation Analysis

Compensation vs Market: Pat's total compensation ($USD3.42M) is above average for companies of similar size in the US market ($USD2.45M).

Compensation vs Earnings: Pat's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CRY's management team is seasoned and experienced (6.2 years average tenure).


Board Members

Experienced Board: CRY's board of directors are considered experienced (9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CRY insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.6%.


Top Shareholders

Company Information

CryoLife, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CryoLife, Inc.
  • Ticker: CRY
  • Exchange: NYSE
  • Founded: 1984
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$1.133b
  • Shares outstanding: 39.10m
  • Website: https://www.cryolife.com

Number of Employees


Location

  • CryoLife, Inc.
  • 1655 Roberts Boulevard N.W.
  • Kennesaw
  • Georgia
  • 30144
  • United States

Listings


Biography

CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linki...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/17 00:48
End of Day Share Price2021/05/14 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.